Switching from intravenous tocilizumab to subcutaneous administration during COVID-19 pandemic: impact on treatment efficacy and patient satisfaction
Authors' conclusion
More than half of the patients who switched from IV TCZ to SC TCZ showed signs of flare of their underlying disease or were less satisfied with SC treatment.
Study context
- Population
- Patients treated with IV TCZ (mean age 53.03 (± 15.7); TCZ for 6.35 (±2.89) years; mostly low disease activity) switched to SC TCZ during the COVID-19 pandemic, Rambam Health Care Campus, Israel3 excluded
- Participants
- 40 patients
- Exposure
- Switch from IV tocilizumab to SC tocilizumab
- SC TCZn = 40
- Outcome
- Efficacy and patient satisfaction of SC TCZ after switching from IV TCZ
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
SC TCZ
70%
26
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Continued SC TCZ | SC TCZ 30% |
| Less satisfaction with SC TCZ among those continuing | SC TCZ 27% |
- Continued SC TCZ: 11/37
- Less satisfaction with SC TCZ among those continuing: 3/11
Safety
Hospitalisation for IV GC (flare after switch to SC TCZ)
- Patients hospitalised for IV GC
- 2
Knee arthrocentesis (flare after switch to SC TCZ)
- Patients who underwent knee arthrocentesis
- 1
Original publication
Switching from intravenous tocilizumab to subcutaneous administration during COVID-19 pandemic: impact on treatment efficacy and patient satisfaction. Clin Exp Rheumatol. Published 16 March 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →